|
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
NOT_RECRUITINGPhase 1Sponsored by USWM CT, LLC
No longer actively recruiting
PhasePhase 1
SponsorUSWM CT, LLC
Started2018-04-09
Est. completion2032-04-01
Eligibility
Healthy vol.Accepted
Locations13 sites
View on ClinicalTrials.gov →
NCT03391778
Summary
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Eligibility
Healthy volunteers accepted
Inclusion Criteria: * Participants who have received at least one dose of ADP adoptive cell therapy agent. * Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it. * Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy. * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * The investigator is responsible for review of medical history. * Capable of giving signed informed consent. Exclusion Criteria: \- None
Conditions2
CancerNeoplasms
Interventions1
Locations13 sites
National Cancer Institute - Center for Cancer Research
University of Michigan
Ann Arbor, Michigan, 48109
Clinical Trial Inquiries
Washington University School of Medicine in St. Louis
Clinical Trial Inquiries
Find trials near these locations
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
No longer actively recruiting
PhasePhase 1
SponsorUSWM CT, LLC
Started2018-04-09
Est. completion2032-04-01
Eligibility
Healthy vol.Accepted
Locations13 sites
View on ClinicalTrials.gov →
NCT03391778